The design and development of DaunoXome® for solid tumor targeting in vivo

Advanced Drug Delivery Reviews

Volumn 24, Issue 2-3, 1997, Pages 133-150

  Forssen, Eric A ^a  

^a NeXstar Pharmaceuticals Inc   (United States)

Author keywords

ABV therapy; antineoplastic agent delivery; daunorubicin; distearolyphosphatidylcholine (DSPC) cholesterol liposomes; toxicity

Indexed keywords

AGENTS; BIOMEDICAL ENGINEERING; CHOLESTEROL; COMPOSITION; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; LIPIDS; PHARMACOKINETICS; PHYSICAL PROPERTIES; TOXICITY;

ANTINEOPLASTIC AGENT DELIVERY; DAUNORUBICIN; DAUNOXOME; DISTEAROLYPHOSPHATIDYLCHOLINE; KAPOSI SARCOMA; LIPOSOME DELIVERY SYSTEM; SOLID TUMOR TARGETING;

DRUG THERAPY;

BLEOMYCIN; CHOLESTEROL; DAUNORUBICIN; DISTEAROYLPHOSPHATIDYLCHOLINE; INDIUM 111; LIPOSOME; VINCRISTINE;

ALOPECIA; ANIMAL MODEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACCUMULATION; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; HUMAN; IMAGING; KAPOSI SARCOMA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PARTICLE SIZE; PHASE TRANSITION; PRIORITY JOURNAL; SOLID TUMOR; SURFACE CHARGE;

EID: 0342617568     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00453-X     Document Type: Conference Paper

References (107)

1. Kirby, C. and Gregoriadis, G. (1983) The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice. Biochem. Pharmacol., 32, 609-615.
2. Juliano, R.L. and Stamp, D. (1978) Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Biochem. Pharmacol., 27, 21-27.
3. Freise, J., Mueller, W.H., Magerstedt, P., and Schmoll, H.J. (1982) Pharmacokinetics of liposome encapsulated cisplatin in rats. Arch. Int. Pharmacodyn. Ther., 258, 180-192.
4. Allen, T.M. and Everest, J.M. (1983) Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J. Pharmacol. Exp. Ther., 226, 539-544.
5. Patel, H.M. (1989) Transcytosis of drug carriers carrying peptides across epithelial barriers. Biochem. Soc. Trans., 17, 940-942.
6. Postmes, T.J., Hukkelhoven, M. van den Bogaard, A.E., Halders, S.G. and Coenegracht, J. (1980) Passage through the blood-brain barrier of thyrotropin-releasing hormone encapsulated in liposomes. J. Pharm. Pharmacol., 32, 722-724.
7. Tökés, Z.A., St. Peteri, A.K. and Todd, J.A. (1980) Availability of liposome content to the nervous system. Liposomes and the blood-brain barrier. Brain Res., 188, 282-286.
8. D Silva, J.B. and Notari, R.E. (1982) Drug stability in liposomal suspensions: hydrolysis of indomethacin, cyclocytidine, and p-nitrophenyl acetate. J. Pharm. Sci., 71, 1394-1398.
9. Fiore, S. and Serhan, C.N. (1989) Phospholipid bilayers enhance the stability of leukotriene A4 and epoxytetraenes: stabilization of eicosanoids by liposomes. Biochem. Biophys. Res. Commun., 159, 477-481.
10. Kurosaki, Y., Kimura, T., Muranishi, S. and Sezaki, H. (1981) The use of liposomes as enzyme carriers. I. Dependence of enzyme stability on the method of preparation. Chem. Pharm. Bull. (Tokyo), 29, 1175-1178.
11. Patel, K.R. and Baldeschwieler, J.D. (1984) Mouse Lewis lung carcinoma and hepatoma ascites treatment by combination of liposome chemotherapy and non-specific immunotherapy. Int. J. Cancer, 34, 717-723.
12. Kim, S. (1993) Liposomes as carriers of cancer chemotherapy. Current status and future prospects. Drugs, 46, 618-638.
13. Gabizon, A., Meshorer, A. and Barenholz, Y. (1986) Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst., 77, 459-469.
14. Kennedy, K.A., Teicher, B.A., Rockwell, S. and Sartorelli, A.C. (1980) The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol., 29, 1-8.
15. Jain, R.K. (1996) Delivery of molecular medicine to solid tumors. Science, 271, 1079-1080.
16. Netti, P.A., Baxter, L.T., Boucher, Y., Skalak, R. and Jain, R.K. (1995) Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res., 55, 5451-5458.
17. Less, J.R., Skalak, T.C., Sevick, E.M. and Jain, R.K. (1991) Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res., 51, 265-273.
18. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1, 27-31.
19. Martiny-Baron, G. and Marine, D. (1995) VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Curr. Opin. Biotechnol., 6, 675-680.
20. Jahroudi, N. and Greenberger, J.S. (1995) The role of endothelial cells in tumor invasion and metastasis. J. Neurooncol., 23, 99-108.
21. Weiss, L., Orr, F.W. and Honn, K.V. (1989) Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis. Clin. Exp. Metastasis, 7, 127-167.
22. Bikfalvi, A. (1995) Significance of angiogenesis in tumour progression and metastasis. Eur. J. Cancer, 31A, 1101-1104.
23. Rak, J.W., St Croix, B.D. and Kerbel, R.S. (1995) Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs, 6, 3-18.
24. Chaplain, M.A., Giles, S.M., Sleeman, B.D. and Jarvis, R.J. (1995) A mathematical analysis of a model for tumour angiogenesis. J. Math. Biol., 33, 744-770.
25. Skinner, S.A., Tutton, P.J. and Pe, O.B. (1990) Microvascular architecture of experimental colon tumors in the rat. Cancer Res., 50, 2411-2417.
26. Byrne, H.M. and Chaplain, M.A. (1995) Mathematical models for tumour angiogenesis: numerical simulations and nonlinear wave solutions. Bull. Math. Biol., 57, 461-486.
27. Hwang, K.J. and Mauk, M.R. (1977) Fate of lipid vesicles in vivo: a gamma-ray perturbed angular correlation study. Proc. Natl. Acad. Sci. USA, 74, 4991-4995.
28. Mauk, M.R. and Gamble, R.C. (1979) Stability of lipid vesicles in tissues of the mouse: a gamma-ray perturbed angular correlation study. Proc. Natl. Acad. Sci. USA, 76, 765-769.
29. Mauk, M.R., Gamble, R.C. and Baldeschwieler, J.D. (1980) Vesicle targeting: timed release and specificity for leukocytes in mice by subcutaneous injection. Science, 207, 309-311.
30. Mauk, M.R. and Gamble, R.C. (1979) Preparation of lipid vesicles containing high levels of entrapped radioactive cations. Anal Biochem., 94, 302-307.
31. Leipert, T.K., Baldeschwieler, J.D. and Shirley, D.A. (1968) Applications of gamma ray angular correlations to the study of biological macromolecules in solution. Nature, 220, 907-909.
32. Meares, C.F., Bryant, R.G., Baldeschwieler, J.D. and Shirley, D.A. (1969) Study of carbonic anhydrase using perturbed angular correlations of gamma radiation. Proc. Natl. Acad. Sci. USA, 64, 1155-1161.
33. Hwang, K.J. (1984) The use of gamma-ray perturbed angular correalation technique for the study of liposomal integrity in vitro and in vivo. In: P.D.G. Gregoriadis (Ed.), Targeted Drug Delivery and Biological Interaction. CRC Press, Boca Raton, FL, pp. 248-262.
34. Baldeschwieler, J.D. (1985) Phospholipid vesicle targeting using synthetic glycolipid and other determinants. Ann. NY Acad. Sci., 446, 349-367.
35. Meares, C.F., Sundberg, M.W. and Baldeschwieler, J.D. (1972) Perturbed angular correlation study of a haptenic molecule. Proc. Nat. Acad. Sci., USA 69, 3718-3722.
36. Goodwin, D.A., Meares, C.F. and Song, C.H. (1972) The study of 111 In-labeled compounds in mice, using perturbed angular correlations of gamma radiations. Radiology, 105, 699-702.
37. Martin, P.W. and Skov, K. (1978) In-111 transferrin labeling studied by perturbed angular correlations. J. Nucl. Med., 19, 1171-1174.
38. Hwang, K.J., Luk, K.F.S. and Beaumier, P.L. (1982) Volume of distribution and transcapillary passage of small unilamellar vesicles. Life Sci., 31, 949-955.
39. Mauk, M.R., Gamble, R.C. and Baldeschwieler, J.D. (1980) Targeting of lipid vesicles: specificity of carbohydrate receptor analogues for leukocytes in mice. Proc. Natl. Acad. Sci. USA, 77, 4430-4434.
40. Proffitt, R.T., Williams, L.E., Presant, C.A., Tin, G.W., Uliana, J.A., Gamble, R.C. and Baldeschwieler, J.D. (1983) Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice. J. Nucl. Med., 24, 45-51.
41. Williams, L.E., Duda, R.B., Proffitt, R.T., Beatty, B.G., Beatty. J.D., Wong, J.Y., Shively, J.E. and Paxton, R.J. (1988) Tumor uptake as a function of tumor mass: a mathematic model. J. Nucl. Med., 29, 103-109.
42. Wallingford, R.H. and Williams, L.E. (1985) Is stability a key parameter in the accumulation of phospholipid vesicles in tumors? J. Nucl. Med., 26, 1180-1185.
43. Ogihara-Umeda, I. and Kojima, S. (1989) Cholesterol enhances the delivery of liposome-encapsulated gallium-67 to tumors. Eur. J. Nucl. Med., 15, 612-617.
44. Proffitt, R.T., Williams, L.E., Presant, C.A., Tin, G.W., Uliana, J.A., Gamble, R.C. and Baldeschwieler, J.D. (1983) Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. Science, 220, 502-505.
45. Turner, A.F., Presant, C.A., Proffitt, R.T., Williams, L.E., Winsor, D.W. and Werner, J.L. (1988) In-111-labeled liposomes: dosimetry and tumor depiction. Radiology, 166, 761-765.
46. Presant, C.A., Proffitt, R.T., Turner, A.F., Williams, L.E., Winsor, D., Werner, J.L., Kennedy, P., Wiseman, C. et al. (1988) Successful imaging of human cancer with indium-111-labeled phospholipid vesicles. Cancer, 62, 905-911.
47. Patel, K.R., Tin, G.W., Williams, L.E. and Baldeschwieler, J.D. (1985) Biodistribution of phospholipid vesicles in mice bearing Lewis lung carcinoma and granuloma. J. Nucl. Med., 26, 1048-1055.
48. Williams, L.E., Proffitt, R.T. and Lovisatti, L. (1984) Possible applications of phospholipid vesicles (liposomes) in diagnostic radiology. J. Nucl. Med. Allied Sci., 28, 35-45.
49. Presant, C.A., Blayney, D., Proffitt, R.T., Turner, A.F., Williams, L.E., Nadel, H.I., Kennedy, P., Wiseman, C. et al. (1990) Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. Lancet, 335, 1307-1309.
50. McNeil, B.J. (1979) Guidlines for evaluating new tests. In: A.F.G. Rocha and J.C. Harbert (Eds.), Textbook of Nuclear Medicine: Clinical Applications. Lea and Febiger, Philadelphia, PA, pp. 473-484.
51. Dictor, M., Bendsoe, N., Runke, S. and Witte, M. (1955) Major basement membrane components in Kaposi's sarcoma, angiosarcoma and benign vascular neogenesis. J. Cutan. Pathol. (Denmark), 22, 435-441.
52. Albini, A., Barillari, G., Benelli, R., Gallo, R. and Ensoli, B. (1995) Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc. Natl. Acad. Sci. USA, 92, 4838-4842.
53. Schwartz, R.A. (1996) Kaposi's sarcoma: advances and perspectives. J. Am. Acad. Dermatol. 34, 804-814.
54. Morris, C.B., Gendelman, R., Marrogi, A.J., Lu, M., Lockyer, J.M., Alperin-Lea, W. and Ensoli, B. (1996) Immunihistochemical detection of Bcl-2 in AIDS-associated and classical Kaposi's sarcoma. Am. J. Pathol., 148, 1055-1063.
55. Noel, J.C., Hermans, P., Andre, J., Fayt, I., Simonart, T., Verhest, A., Haot, J. and Burny, A. (1996) Herpesvirus-like DNA sequences and Kaposi's sarcoma: relationship with epidemiology, clinical spectrum, and histologic features. Cancer, 77, 2132-2136.
56. Brown, L.F., Tognazzi, K., Dvorak, H.F. and Harrist, T.J. (1996) Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am. J. Pathol., 148, 1065-1074.
57. Wu, N.Z., Klitzman, B., Rosner, G., Needham, D. and Dewhirst, M.W. (1993) Measurement of material extravasation in microvascular networks using fluorescence videomicroscopy. Microvasc. Res., 46, 231-253.
58. Presant, C.A., Scolaro, M., Kennedy, P., Blayney, D.W., Flanagan, B., Lisak, J. and Presant, J. (1993) Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341, 1242-1243.
59. Strugar, J.G., Criscuolo, G.R., Rothbart, D. and Harrington, W.N. (1995) Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. J. Neurosurg., 83, 682-689.
60. Warren, B.A. (1979) The vascular morphology of tumors. In: H.-I. Peterson (Ed.), Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors. CRC Press, Boca Raton, FL, pp. 1-47.
61. Hwang, K.J., Padki, M.M., Chow, D.D., Essien, H.E., Lai, J.Y. and Beaumier, PL. (1987) Uptake of small liposomes by non-reticuloendothelial tissues. Biochim. Biophys. Acta, 901, 88-96.
62. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R. and Fidler, I.J. (1982) Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 42, 1412-1422.
63. Papahadjopoulos, D. and Gabizon, A. (1987) Targeting of liposomes to tumor cells in vivo. Ann. NY Acad. Sci., 507, 64-74.
64. Kerr, D.J. and Kaye, S.B. (1987) Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother. Pharmacol., 19, 1-5.
65. Forssen, E.A. (1988) Chemotherapy with anthracycline liposomes. In: G. Gregoriadis (Ed.), Liposomes as Drug Carriers: Recent Trends and Progress. John Wiley, Chichester, pp. 355-364.
66. Forssen, E.A., Coulter, D.M. and Proffitt, R.T. (1992) Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res., 52, 3255-3261.
67. Kaye, S.B., Boden, J.A. and Ryman, B.E. (1981) The effect of liposome (phospholipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours. Eur. J. Cancer, 17, 279-289.
68. Ganapathi, R., Krishan, A., Wodinsky, I., Zubrod, C.G. and Lesko, L.J. (1980) Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo. Cancer Res., 40, 630-633.
69. Rustum, Y.M., Dave, C., Mayhew, E. and Papahadjopoulos, D. (1979) Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia. Cancer Res., 39, 1390-1395.
70. Forssen, E.A. and Tökés, Z.A. (1981) Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc. Natl. Acad. Sci. USA, 78, 1873-1877.
71. Rahman, A., Kessler, A., More, N., Sikic, B., Rowden, G., Woolley, P. and Schein, P.S. (1980) Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res., 40, 1532-1537.
72. Storm, G., Roerdink, F.H., Steerenberg, P.A., de Jong, W.H. and Crommelin, D.J. (1987) Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res., 47, 3366-3372.
73. van Hoesel, Q.G., Steerenberg, P.A., Crommelin, D.J., van Dijk, A., van Dort, W., Klein, S., Douze, J.M., de Wildt, D.J. et al. (1984) Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat. Cancer Res., 44, 3698-3705.
74. Forssen, E.A. and Tökés, Z.A. (1979) In vitro and in vivo studies with adriamycin liposomes. Biochem. Biophys. Res. Commun., 91, 1295-1301.
75. Forssen, E.A. and Tökés, Z.A. (1983) Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res., 43, 546-550.
76. Gabizon, A.A., Barenholz, Y. and Bialer, M. (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res., 10, 703-708.
77. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A. et al. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54, 987-992.
78. Allen, T.M. (1994) Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci., 15, 215-220.
79. Forssen, E.A. and Ross, M.E. (1994) Daunoxome treatment of soild tumors: preclinical and clinical investigations. J. Liposome Res., 4, 481-512.
80. Weiss, R.B. and Bruno, S. (1981) Daunorubicin treatment of adult solid tumors. Cancer Treat. Rep., 4, 25-28.
81. Von Hoff, D.D., Rozencweig, M., Slavik, M. and Muggia, F.M. (1976) Activity of daunomycin in solid tumors (letter). J. Am. Med. Assoc., 236, 1693.
82. Von Hoff, D.D. (1984) Use of daunorubicin in patients with solid tumors. Semin. Oncol., 11, 23-27.
83. Bosanquet, A.G. (1986) Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics. Cancer Chemother. Pharmacol., 17, 1-10.
84. Iwasaki, H., Liu, Y.P., Nojyo, Y., Ueda, T. and Nakamura, T. (1995) Quantitative description of morphologic changes effected by antileukemic agents in L1210 leukemia cells. Anticancer Res., 15, 133-139.
85. Arcamone, F. (1981) In: F. Arcamone (Ed.), Doxorubicin, Academic Press, New York, pp. 354.
86. Gheuens, E., van der Heyden, S., Elst, H., Eggermont, A., Van Oosterom, A. and De Bruijn, E. (1993) Multidrug resistance in rat colon carcinoma cell lines CC531, CC531mdr+ and CC531rev. Jpn. J. Cancer Res., 84, 1201-1208.
87. Nagasawa, K., Natazuka, T., Chihara, K., Kitazawa, F., Tsumura, A., Takara, K., Nomiyama, M., Ohnishi, N. et al. (1996) Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Cancer Chemother. Pharmacol., 37, 297-304.
88. Michieli, M., Michelutti, A., Damiani, D., Pipan, C., Raspadori, D., Lauria, F. and Baccarani, M. (1993) A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leuk. Lymphoma, 9, 255-264.
89. Forssen, E.A., Malé-Brune, R., Adler-Moore, J.P., Lee, M.J., Schmidt, P.G., Krasieva, T.B., Shimizu, S. and Tromberg, B.J. (1996) Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res., 56, 2066-2075.
90. Corbett, T.H., Griswold, D.P.J., Roberts, B.J., Peckham, J.C. and Schabel, F.M.J. (1978) Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat. Rep., 62, 1471-1488.
91. Casazza, A.M. (1979) Experimental evaluation of anthracycline analogs. Cancer Treat. Rep., 63, 835-844.
92. Gibaldi, M. and Perrier, D. (1975) In: Drugs and the Pharmaceutical Sciences J. Swarbrick (Ed.), Pharmacokinetics. Vol. 1, Marcel Dekker, Inc., New York, pp. 329.
93. Tsou, K.C., Lo, K.W., Ledis, S.L. and Miller, E.E. (1972) Indigogenic phosphodiesters as potential chromogenic cancer chemotherapeutic agents. J. Med. Chem. 15, 1221-1225.
94. Ipsen, J.H., Karlstrom, G., Mouritsen, O.G., Wennerstrom, H. and Zuckermann, M.J. (1987) Phase equilibria in the phosphatidylcholine-cholesterol system. Biochim. Biophys. Acta, 905, 162-172.
95. Papahadjopoulos, D., Cowden, M. and Kimelberg, H. (1973) Role of cholesterol in membranes. Effects on phospholipid-protein interactions, membrane permeability and enzymatic activity. Biochim. Biophys. Acta, 330, 8-26.
96. Papahadjopoulos, D., Jacobson, K., Nir, S. and Isac, T. (1973) Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim. Biophys. Acta, 311, 330-348.
97. Kirby, C., Clarke, J. and Gregoriadis, G. (1980) Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J., 186, 591-598.
98. Gill, P.S., Espina, B.M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J.A., Liebman, H.A., Forssen, E. et al. (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol., 13, 996-1003.
99. Money-Kyrle, J.F., Bates, F., Ready, J., Gazzard, B.G., Phillips, R.H. and Boag, F.C. (1993) Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin. Oncol. (R. Coll. Radiol.), 5, 367-371.
100. Gill, P.S., Wernz, J., Scadden, D.T., Cohen, P., Mukwaya, G.M., von Roenn, J.H., Jacobs, M., Kempin, S. et al. (1996) Randomized phase III trial of liposomal daunorubicin (DaunoXome) versus doxorubicin, bleomycin, vincristine, (ABV) in AIDS-related Kaposi's sarcoma. J. Clin. Oncology, 14, 2353-2364.
101. Gill, P.S., Naidu, Y.M. and Salahuddin, S.Z. (1990) Recent advances in AIDS-related Kaposi's sarcoma. Curr. Opin. Oncol., 2, 1161-1166.
102. Krown, S.E. (1987) The role of interferon in the therapy of epidemic Kaposi's sarcoma. Semin. Oncol., 14, 27-33.
103. Kaplan, S.B. (1992) Neoplastic complications in HIV disease. Infect. Med., 9, 20.
104. Northfelt, D.W., Kahn, J.O. and Volberding, P.A. (1991) Treatment of AIDS-related Kaposi's sarcoma. Hematol. Oncol. Clin. North Am., 5, 297-310.
105. Schurmann, D., Dormann, A., Grunewald, T. and Ruf, B. (1994) Successful treatment of AIDS-related pulmonary Kaposi's sarcoma with liposomal daunorubicin. Eur. Respir. J., 7, 824-825.
106. Hengge, U.R., Brockmeyer, N.H., Rasshofer, R. and Goos, M. (1993) Fatal hepatic failure with liposomal doxorubicin [letter]. Lancet, 341, 383-384.
107. Dorr, R.T. and Von Hoff, D.D. (Eds.) (1994) Cancer Chemotherpy Handbook. 2nd ed., Appleton and Lange: Norwalk, CT, p. 1020.